WuXi AppTec report shows prospects of immunotherapy treatments for cancer
China-based company WuXi AppTec has published a new report highlighting the prospects of immunotherapy as a potential treatment for cancer.
The report claims that smaller, nimble biotechs and early stage companies will serve as the single biggest factor behind the advanced approaches in the development of immunotherapy treatments.
The coming five years is reported to be the most important phase in the fight against cancer with the use of immunotherapies, such as chimeric antigen receptor (CAR)-T and moderating T-cell approaches, and innate immunity therapies.
In addition, the WuXi AppTec report anticipates significant breakthroughs in the field of immunotherapy treatments over the next ten years with improvement in the industry’s understanding of the immune system.
More than 130 biotechnology firms and 20 major pharmaceutical companies are currently working on the new therapies, while smaller businesses are reported to introduce latest treatments in the market.
WuXi AppTec Corporate Alliances vice-president and communications head Hui Cai said: “The current investor frenzy is comparable to that of the genomics industry at the turn of the century.
“The experts we speak with argue that a more complete understanding of the genome and promise of clinical data of these transformative modalities will create a golden age for cancer therapy emerge over the next few years.”
However, according to the report, the development of newest cancer treatments is expected to face several immediate challenges.
The extent to which all cancer patients can be cured, particularly the ones with late-stage metastatic cancer, is yet to be determined.
CAR-T shows good efficacy in blood cancers and is yet to demonstrate enough efficacy in treating solid tumours.
The report claims immunotherapies are taking cancer from treatment options that simply extend life or improve experience to more effective cures.
WuXi AppTec’s pharmaceutical development services (PDS) division merged with STA Pharmaceutical in July.